Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1421. Faecal occult blood screening for colorectal cancer: is it cost-effective?

Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Whynes D K, Neilson A R, Walker A R, Hardcastle J D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the faecal occult blood (FOB) test for colorectal cancer (CRC) screening in an unselected population of men and women aged 50 to 74 years; those in the pilot study were aged 45 to 74 years. Type of intervention Screening. Economic study type Cost-utility analysis. Study population The study population comprised unselected men and women aged 50 to 74 years; the pilot study involved

1998 NHS Economic Evaluation Database.

1422. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers

relevance and validity, and for extracting data Not stated. Number of primary studies included Four studies were included. Estimates of the lifetime risk of developing CRC and the stage distribution of CRC for symptomatic patients were derived from the Dutch hereditary nonpolyposis colorectal carcinoma (HNPCC) registry. The CRC stage specific relative survival rates and the effectiveness of surveillance in preventing or detecting cancer early were based on Finnish studies. Methods of combining primary (...) gene carriers. Cancer 1998; 82(9): 1632-1637 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Colonoscopy /economics; Colorectal Neoplasms, Hereditary Nonpolyposis /diagnosis /economics /genetics; Cost-Benefit Analysis; Genetic Testing /economics; Heterozygote; Humans; Male; Middle Aged AccessionNumber 21998000644 Date bibliographic record published 31/10/1999 Date abstract record published 31/10/1999 NHS Economic Evaluation Database (NHS EED) Produced by the Centre

1998 NHS Economic Evaluation Database.

1423. Colorectal cancer screening: efficiency and effectiveness

issues The issue of generalisability to other settings was addressed and appropriate comparisons with other studies were made by the authors. Source of funding None stated. Bibliographic details Gyrd-Hansen D, Sogaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Economics 1998; 7: 9-20 PubMedID Other publications of related interest Comment in: Health Economics 1998;7(1):1-7. Indexing Status Subject indexing assigned by NLM MeSH Aged; Colorectal Neoplasms (...) Colorectal cancer screening: efficiency and effectiveness Colorectal cancer screening: efficiency and effectiveness Colorectal cancer screening: efficiency and effectiveness Gyrd-Hansen D, Sogaard J, Kronborg O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

1998 NHS Economic Evaluation Database.

1424. Assessing the resectability of pancreatic carcinoma: the value of reinterpreting abdominal CT performed at other institutions Full Text available with Trip Pro

adenocarcinoma of the pancreas and this was reflected in the authors' conclusions. The authors did not have proper data to analyse the effect of technique or film type on discrepancies. The authors did not document when initial reports were reviewed by radiologists or when the discrepancies were resolved except in one case involving resolution by repeat abdominal CT, which occurred 165 days after the initial CT; the authors acknowledge that this may have been influenced by disease progression. Implications (...) Adenocarcinoma /radiography /surgery; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms /radiography /surgery; Radiography, Abdominal; Retrospective Studies; Tomography, X-Ray Computed AccessionNumber 21998001788 Date bibliographic record published 31/12/2001 Date abstract record published 31/12/2001 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed record

1998 NHS Economic Evaluation Database.

1425. Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer Full Text available with Trip Pro

Unit costs associated with the double contrast barium enema, the other screening tests, the diagnostic procedures and tissue pathology were included, as were the lifetime costs of treating both early and late identified colorectal cancer and the costs of treating a perforated colon, a possible complication associated with colorectal cancer screening. The resource quantities were derived from the model although they were not detailed separately. Costs were discounted at an annual rate of 5 (...) detection of colorectal cancer. Philadelphia: Saunders, 1996:321-356. Indexing Status Subject indexing assigned by NLM MeSH Barium Sulfate /administration & Colorectal Neoplasms /economics /mortality /radiography; Contrast Media /economics; Cost-Benefit Analysis; Enema; Humans; Middle Aged; Models, Statistical; Quality-Adjusted Life Years; Sensitivity and Specificity; Survival Rate; dosage /economics AccessionNumber 21998000393 Date bibliographic record published 31/10/1999 Date abstract record

1998 NHS Economic Evaluation Database.

1426. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. (Abstract)

Leucovorin U3P01618RT Fluorouracil IM Ann Oncol 1997 Apr;8(4):407 Adenocarcinoma drug therapy Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic therapeutic use Antineoplastic Combined Chemotherapy Protocols therapeutic use Colorectal Neoplasms drug therapy Female Fluorouracil administration & dosage Follow-Up Studies Humans Leucovorin administration & dosage Longitudinal Studies Male Middle Aged Quinazolines therapeutic use Thiophenes therapeutic use 1996 11 1 1996 11 1 0 1 1996 11 1 0 0 (...) Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. 9006748 1997 04 02 2016 10 17 0923-7534 7 9 1996 Nov Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study

1997 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

1427. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. (Abstract)

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. The efficacy of chemotherapy may be affected by circadian rhythms. Therefore, we tested chronomodulated infusion (administered to coincide with relevant circadian rhythms) of oxaliplatin, fluorouracil, and folinic acid compared with a constant-rate infusion method. The combination of three drugs was delivered for 5 (...) -day courses with 16-day intervals.We expected chronotherapy to increase objective response rate by 20% compared with constant-rate infusion. We tested this effect in a randomised multicentre trial involving patients with previously untreated metastases from colorectal cancer who were enrolled at nine institutions in three countries. 93 patients were assigned chronotherapy and 93 were assigned constant-rate infusion via multichannel programmable ambulatory pumps. The trial was interrupted when

1997 Lancet Controlled trial quality: uncertain

1428. Colorectal cancer screening

Colorectal cancer screening Colorectal cancer screening Colorectal cancer screening Australian Health Technology Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Australian Health Technology Advisory Committee. Colorectal cancer screening. Canberra: Australian Health Technology Advisory Committee (AHTAC) 1997: 147 (...) Authors' objectives The aim of this review is to assess the evidence on the benefits, risks and costs of colorectal cancer (CRC) screening, and to make recommendations to the Minister on whether a programme of population screening should be introduced in Australia. Authors' conclusions This report has assessed the scientific evidence from the three completed international RCTs and, where RCTs are not available, the results of strong and intermediate strength studies. On balance, AHTAC considers

1997 Health Technology Assessment (HTA) Database.

1429. Aspirin in the primary prevention of cardiovascular disease and colon cancer

cancer. ASA prophylaxis is effective in various groups who are at high risk for cardiovascular disease. However, more effective treatments are available for some conditions, such as atrial fibrillation, which are associated with a high risk of stroke, though such treatments are associated with a higher risk of complications. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin /therapeutic use; Cerebrovascular Disorders; Colorectal Neoplasms; Myocardial Infarction (...) Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Hailey D, Harstall C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D, Harstall C. Aspirin

1997 Health Technology Assessment (HTA) Database.

1430. Participation in colorectal cancer screening: a review

into account, is warranted. Funding Public Health Service, grant number CA52605. Bibliographic details Vernon S W. Participation in colorectal cancer screening: a review. Journal of the National Cancer Institute 1997; 89(19): 1406-1422 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Colorectal Neoplasms /diagnosis /prevention & Demography; Female; Great Britain; Health Promotion; Humans; Male; Mass Screening /statistics & Middle Aged; Occult Blood; Reproducibility (...) Participation in colorectal cancer screening: a review Participation in colorectal cancer screening: a review Participation in colorectal cancer screening: a review Vernon S W Authors' objectives To study the prevalence, interventions to improve adherence to, predictors of adherence to, and reasons for nonadherence to faecal occult blood testing (FOBT) and sigmoidoscopy for colorectal cancer screening. Searching The following sources were searched: MEDLINE, Cancerlit and PsycINFO, all from 1973

1997 DARE.

1431. Adjuvant therapy for stage III colon cancer after complete resection

with 5-FU by portal vein infusion (PVI); 1 treatment regimen versus 1 or more other treatment regimens; Immunotherapy; and Oral 5-FU therapy. Participants included in the review Patients with resected stage III colon cancer. Outcomes assessed in the review The main outcome of interest was overall survival. Secondary outcomes of interest were disease-free survival and adverse effects of the treatment regimes. How were decisions on the relevance of primary studies made? The authors do not state how (...) %. When trials were separated according to the type of treatment given, the significant ORs were for 5-FU plus either levamisole (OR=0.61; 95% CI: 0.46,0.80) or leucovorin (OR=0.51; 95% CI: 0.36,0.73). Three recently reported trials comparing various combinations of 5-FU plus leucovorin, with or without levamisole, showed similar improvements in disease-free and overall survival. Authors' conclusions Patients with resected stage III colon cancer should be offered adjuvant therapy. The regimen of 5-FU

1997 DARE.

1432. Adjuvant therapy for stage II colon cancer after complete resection

: The authors state that adjuvant therapy is not recommended at this time for the routine management of patients with resected stage II colon cancer. Patients with stage II disease and high-risk factors (bowel obstruction, tumour adhesion, invasion, perforation, or aneuploidy) have a poorer prognosis, similar to that of patients with stage III colon cancer. For individual management, these patients should be made aware of their prognosis; treatment can be considered after the uncertainty of the value (...) development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12. 2. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4,000 patients in 10 studies. J Natl Cancer Inst 1997;89:497-505. Indexing Status Subject indexing assigned by NLM MeSH Chemotherapy, Adjuvant; Colonic Neoplasms /therapy; Combined Modality Therapy; Fluorouracil /therapeutic use; Humans; Immunotherapy; Levamisole /therapeutic use

1997 DARE.

1433. Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons

Society of Colon and Rectal Surgeons Richard C S, McLeod R S Authors' objectives To evaluate the effectiveness of post-operative follow-up surveillance of patients with colorectal carcinoma. Searching [AC:The search strategy folloed the methods of the Canadian Task Force for the Periodic Health Examination]. MEDLINE was searched from 1966 to February 1996 for English and French articles using the MeSH 'colorectal neoplasm' and 'follow-up studies'. Relevant references from retrieved literature (...) Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian

1997 DARE.

1434. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies

Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Liver Infusion Meta-analysis Group Authors' objectives To assess the effects on tumour recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by portal vein infusion (PVI) after colorectal (...) by PVI for patients with colorectal cancer. Research: The authors stated that further large trials of post-operative treatment with 5-FU by PVI in patients with colorectal cancer are needed. Funding Imperial Cancer Research Fund; the Ligue Nationale Francaise Contre le Cancer; the Conseil General du Val de Marne; BIOMED Programme of the European Community, grant number PL 931247. Bibliographic details Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis

1997 DARE.

1435. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis

are not reported and the reader would have to obtain the individual reports to ascertain facts such as patient age range and gender. Without details of study design or patient characteristics, it is not clear to which patients with rectal carcinoma the results of the meta-analysis would be applicable. Bibliographic details Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Diseases of the Colon and Rectum 1997; 40(1): 35-41 PubMedID Other publications (...) of follow-up, were included. Specific interventions included in the review Adjuvant chemotherapy including 5-fluorouracil. Participants included in the review Patients with Dukes C colon cancer receiving adjuvant chemotherapy and patients with Dukes B or C rectal carcinoma receiving radiotherapy and chemotherapy, were included. Trials involving liver perfusion were excluded. Outcomes assessed in the review The outcome was 5-year survival. How were decisions on the relevance of primary studies made

1997 DARE.

1436. Is it cost effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation

details Gyrd-Hansen D. Is it cost effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation. 1997; 41: 189-199 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Colonic Neoplasms /prevention & Cost-Benefit Analysis; Denmark; Female; Health Care Rationing /economics; Health Policy; Humans; Male; Mass Screening /economics; Middle Aged; Rectal Neoplasms /prevention & Uterine Cervical Neoplasms /prevention (...) were the survival rate amongstpatients whose cancers were detected, the rate of adenomas detected due to screening which would have otherwise gone undetected, and the percentage of large adenomas (greater or equal to 1 cm in diameter). Effectiveness results It was reported that the mortality rate for colorectal cancer, over a period of 10 years "was significantly reduced in the screening group (mortality ratio 0.82 (0.68-0.99))". The survival rate amongst the patients whose cancers were detected

1997 NHS Economic Evaluation Database.

1437. Prevention of colorectal cancer: costs and effectiveness of sigmoidoscopy

of various screening scenarios to the public, the development of optimal endoscopy procedures tailored to the specific demands ofscreening interventions and expected savings on the treatment of colorectal cancer. Source of funding Supported by the Dutch 'Praeventienfonds' and by the Dutch Digestive Disease Foundation. Bibliographic details Geul K W, Bosman F T, van Blankenstein M, Grobbee D E, Wilson J H. Prevention of colorectal cancer: costs and effectiveness of sigmoidoscopy. Scandinavian Journal (...) of adenomas per colon. There were 100 autopsies in each of three age groups (50-59, 60-69 and 70-79). Study design The study was a cohort study. Analysis of effectiveness The primary outcome used in the analysis was the number of adenomas eliminated by an endoscopy programme. Effectiveness results An initial full colonoscopy could potentially detect 45 adenomas per 100 of the population, corresponding with a reduction of 60% in the total colorectal cancer risk in the population. Adequate follow-up

1997 NHS Economic Evaluation Database.

1438. Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing

Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta (...) A, Mantellini P, Ciatto S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two faecal occult blood tests (FOBT) for colorectal cancer screening: Hemoccult (guaiac based) and reversed passive hemagglutination (RPHA) tests. RPHA tests were

1997 NHS Economic Evaluation Database.

1439. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis

) Dukes' B or C who were under 75 years old, had no concomitant malignancy, ulcerative colitis, Crohn's disease, renal, heart or liver failure and who were capable of undergoing one year of adjuvant therapy, were invited to participate. 95 patients were recruited, one patient proved to have Dukes' A and was excluded, so 94 (53 females, 41 males) were included. Their median age at diagnosis was 62 years (range: 36-76 years), 72% had colonic carcinoma and 64% had Dukes' B and 34% Dukes' C CRC. 47 were (...) randomised to surgery plus ACT and 47 to surgery alone. Setting Patients were recruited from the three counties of northern Norway: Finmark (23), Troms (32) and Nordland (39). Patients were treated at the University Hospital of Tromso (UHT) and 8 other local hospitals. Dates to which data relate Patients were recruited from January 1993 to February 1996. Patient records were analysed in April 1996 with respect to sex, age at diagnosis, tumour location (rectal or colonic carcinoma), Dukes' stage (B or C

1997 NHS Economic Evaluation Database.

1440. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer

A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Annals of Oncology 1997;8:65-70. Pihl E, Hughes ES, McDermot FT, et al. Disease free survival and recurrence after resection of colorectal cancer. Journal of Surgical Oncology 1981;16:333-41. Indexing Status Subject indexing assigned by NLM MeSH Carcinoembryonic Antigen /analysis /economics; Colonic Neoplasms /economics /mortality /therapy; Colonoscopy; Cost-Benefit Analysis (...) limitations. The authors recommend considering the exclusion of CEA monitoring as an indicator for second-look surgery, which can improve the cost-effectiveness of the follow-up programme. Source of funding None stated. Bibliographic details Norum J, Olsen J A. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Annals of Oncology 1997; 8: 1081-1087 PubMedID Other publications of related interest Berge I, Ekelund C, Mellner BP. Carcinoma of the colon and rectum

1997 NHS Economic Evaluation Database.